Touch Medical Media coverage of data presented at EADV 2022:
Apremilast is an oral small-molecule inhibitor of PDE4 currently approved in adult patients with plaque psoriasis. It was a pleasure to talk with Dr. Loretta Fiorillo (University of Alberta, Edmonton, Canada) around the unmet needs in the treatment of plaque psoriasis in paediatric patients and the clinical evidence supporting apremilast in this indication.
The abstract ‘Efficacy and Safety of Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: 16-Week Results From a Phase 3, Randomized, Double Blind, Placebo-Controlled Study.’ ( Presentation ID D1T01.3E) was presented at EADV 2022, 7-10 September, 2022.
Questions:
- What are the unmet needs in the treatment of plaque psoriasis in paediatric patients? (0:26)
- What is apremilast, and what clinical evidence supports its use in the treatment of plaque psoriasis? (2:16)
Disclosures: Loretta Fiorillo discloses receiving grant/ research support from Amgen, Pfizer, Galderma, Leo, and Timber; and serving on advisory boards for Amgen, Pfizer, Galderma, Leo, and Timber.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
This content was developed by Touch Medical Media and is not affiliated with the European Academy of Dermatology & Venereology (EADV) or the congress.
